智通财经APP讯，大成生化科技(00809)发布公告，执行董事兼本集团首席营运官(COO)王贵成先生(王 先生)已由其COO职位调任为本公司总经理(总经理)，自2025年12月18日起生效。此次调任乃本公司(作 为吉林省具有国有背景的企业)人力资源架构安排的一部分，以符合本集团未来业务发展需要。于调任 后，王先生将继续负责监督本集团的营运管理及产品开发，并担任本公司行政总裁职务。 ...

格隆汇12月18日丨大成生化科技(00809.HK)宣布，执行董事兼集团首席营运官(「COO」)王贵成已由其 COO职位调任为公司总经理(「调任」)，自2025年12月28日起生效。 ...

大成生化科技(00809)发布公告，执行董事兼本集团首席营运官(COO)王贵成先生(王先生)已由其COO职 位调任为本公司总经理(总经理)，自2025年12月18日起生效。此次调任乃本公司(作为吉林省具有国有背 景的企业)人力资源架构安排的一部分，以符合本集团未来业务发展需要。于调任后，王先生将继续负 责监督本集团的营运管理及产品开发，并担任本公司行政总裁职务。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大 成 生 化 科 技 集 團 有 限 公 司 * （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：00809） — 1 — 調任現任首席營運官為總經理 大成生化科技集團有限公司（「本公司」，連同其不時之附屬公司統稱「本集團」）董事（「董 事」及各稱為「董事」）會（「董事會」）謹此宣佈，執行董事兼本集團首席營運官（「COO」）王 貴成先生（「王先生」）已由其COO職位調任為本公司總經理（「總經理」）（「調任」），自二零 二五年十二月十八日起生效。此次調任乃本公司（作為吉林省具有國有背景的企業）人力 資源架構安排的一部分，以符合本集團未來業務發展需要。於調任後，王先生將繼續負 責監督本集團的營運管理及產品開發，並擔任本公司行政總裁職務。 王先生的履歷詳情載列如下。 王先生，58歲， ...

(Effective as from 1 April 2012 and amended on 30 August 2013 and 18 December 2025) (自2012 年4 月1日起生效及於 2013 年8 月30 日及 2025 年 12 月 18 日修訂) GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大成生化科技集團有限公司 董事會提名委員會職權範圍 Terms of reference of the Nomination Committee of the Board of Directors GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED 大成生化科技集團有限公司 (the "Company" and "本公司") Terms of reference of the Nomination Committee (the "Committee") of the Board (the "Board") of Directors (the "Directors") of the Company ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 大成生化科技集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00809 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | | 0.1 HKD | | 3,000,000,00 ...

Investment Rating - The report does not explicitly state an investment rating for Global Bio-chem Technology Group (0809.HK) Core Insights - The company reported a net loss of HKD 155 million for the first half of 2025, despite a revenue increase of 32.0% year-on-year to HKD 1.186 billion and a gross profit increase of 144.2% to HKD 161 million [1][6] - The company is committed to debt capitalization and has successfully capitalized approximately HKD 301 million of supplier debt, reducing the total by about 34.72% [4][20] - The company aims to lower lysine production costs and plans to complete a boiler renovation project by August 2026 [4][20] - The company is exploring partnerships or investors to enhance operational efficiency and restore production at its Xinglongshan facility [4][20] Summary by Sections Latest Developments - In the first half of 2025, the company achieved revenues of HKD 1.186 billion, a 32.0% increase year-on-year, and a gross profit of HKD 161 million, a 144.2% increase year-on-year [1][6] - The EBITDA for the period was approximately HKD 82.3 million, down from HKD 102 million in the previous year, primarily due to the absence of a one-time government subsidy [1][6] Business Strategy - The company has completed a share issuance to capitalize on supplier debt, resulting in the conversion of HKD 4.61 billion in supplier debt to equity [4][20] - The company is focused on reducing lysine production costs through process optimization and aims to complete a boiler renovation project by August 2026 [4][20] - The company is actively seeking business alliances or investors to enhance operational efficiency and restore production at its Xinglongshan facility [4][20] Market Position - The company is a pioneer in corn refining and biochemical product manufacturing in Asia, with a goal to become the largest integrated manufacturer of corn-based biochemical products in the Asia-Pacific region [5][6] - The company has seen a significant increase in the sales volume of its amino acid segment, which rose by approximately 52.0% to about 187,000 tons [6][10] - The average operating rate for corn starch production in China reached 69.26% in 2024, up from 61.67% in 2023, indicating a positive trend in the upstream corn refining sector [11][12] Financial Performance - The gross profit margin improved from 7.3% in the first half of 2024 to 13.6% in the first half of 2025, reflecting enhanced operational efficiency [16][17] - The company’s administrative and other expenses decreased significantly following the sale of a subsidiary, contributing to improved cash flow and liquidity [16][17] Industry Trends - The global corn production for the 2025/26 season is projected to increase to 1.264 billion tons, driven by expanded planting areas in the U.S. [11][12] - Domestic corn prices in China have been rising steadily, with prices increasing from RMB 2,075 per ton in January 2025 to RMB 2,447 per ton by June 2025 [12][16] - The lysine market is experiencing volatility due to international trade policy uncertainties, with a 5.0% decline in China's lysine export volume in the first half of 2025 [17][18]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 大成生化科技集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00809 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | | 0.1 HKD | | 3,000,000,00 ...

Core Points - The company announced that all conditions precedent under Share Purchase Agreement I and Share Purchase Agreement II have been fulfilled, and the agreements were completed on October 2, 2025 [1] - A total of 2.753 billion shares were issued as consideration shares [1] - The company received a conversion notice from bondholders to fully exercise their conversion rights under the convertible bond, converting HKD 1.086 billion principal amount into 5.173 billion conversion shares at a conversion price of HKD 0.21 per share [1] - After completing the necessary administrative procedures for the issuance of conversion shares, the company issued 5.173 billion conversion shares to bondholders on October 2, 2025, which rank equally with all other existing shares [1]

Core Viewpoint - The company has successfully completed the share purchase agreements, resulting in the issuance of a total of 2.753 billion shares [1] Group 1: Share Purchase Agreements - The board of directors announced that all conditions precedent for Share Purchase Agreement I and Share Purchase Agreement II have been met [1] - The share purchase agreements were completed on October 2, 2025 [1] - A total of 2.753 billion shares have been issued as consideration shares [1] Group 2: Convertible Bonds - The company received a conversion notice from bondholders regarding the full exercise of their conversion rights under the convertible bond issue [1] - The principal amount of HKD 1.086 billion in convertible bonds was converted into 5.173 billion shares at a conversion price of HKD 0.21 per share [1] - After completing the necessary administrative procedures for the issuance of conversion shares, the company issued 5.173 billion conversion shares to bondholders on October 2, 2025 [1]